173 related articles for article (PubMed ID: 26115976)
1. Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
van Kruchten M; van der Marel P; de Munck L; Hollema H; Arts H; Timmer-Bosscha H; de Vries E; Hospers G; Reyners A
Gynecol Oncol; 2015 Sep; 138(3):634-9. PubMed ID: 26115976
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
5. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
9. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.
Kashiwagi E; Fujita K; Yamaguchi S; Fushimi H; Ide H; Inoue S; Mizushima T; Reis LO; Sharma R; Netto GJ; Nonomura N; Miyamoto H
Cancer Biol Ther; 2016 Nov; 17(11):1188-1196. PubMed ID: 27635763
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Meier W; du Bois A; Rau J; Gropp-Meier M; Baumann K; Huober J; Wollschlaeger K; Kreienberg R; Canzler U; Schmalfeldt B; Wimberger P; Richter B; Schröder W; Belau A; Stähle A; Burges A; Sehouli J
Gynecol Oncol; 2012 Aug; 126(2):236-40. PubMed ID: 22564713
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer.
Tang W; Liu R; Yan Y; Pan X; Wang M; Han X; Ren H; Zhang Z
Oncotarget; 2017 Jun; 8(25):40765-40777. PubMed ID: 28388558
[TBL] [Abstract][Full Text] [Related]
13. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract][Full Text] [Related]
15. [Influence of gonadotropin-releasing hormone agonist on the effects of chemotherapy upon ovarian cancer: an experimental study with rat model].
Yuan GW; Shen K; Yang JX
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1428-31. PubMed ID: 16029659
[TBL] [Abstract][Full Text] [Related]
16. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
17. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S; Hennessy BT; Ng CS; Ju Z; Coombes KR; Wolf JK; Sood AK; Levenback CF; Coleman RL; Kavanagh JJ; Gershenson DM; Markman M; Dice K; Howard A; Li J; Li Y; Stemke-Hale K; Dyer M; Atkinson E; Jackson E; Kundra V; Kurzrock R; Bast RC; Mills GB
Gynecol Oncol; 2012 Jul; 126(1):47-53. PubMed ID: 22487539
[TBL] [Abstract][Full Text] [Related]
18. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Lee P; Rosen DG; Zhu C; Silva EG; Liu J
Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
[TBL] [Abstract][Full Text] [Related]
19. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.
Anwer K; Kelly FJ; Chu C; Fewell JG; Lewis D; Alvarez RD
Gynecol Oncol; 2013 Oct; 131(1):169-73. PubMed ID: 23863356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]